InventisBio Co Ltd
SSE:688382
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
12.51
47.9
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
InventisBio Co Ltd
Revenue
InventisBio Co Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
I
|
InventisBio Co Ltd
SSE:688382
|
Revenue
ÂĄ168.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Revenue
ÂĄ27.2B
|
CAGR 3-Years
53%
|
CAGR 5-Years
56%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Revenue
ÂĄ11.4B
|
CAGR 3-Years
36%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Revenue
ÂĄ2.1B
|
CAGR 3-Years
111%
|
CAGR 5-Years
97%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Revenue
ÂĄ2.2B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Revenue
ÂĄ1.9B
|
CAGR 3-Years
291%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
InventisBio Co Ltd
Glance View
Amidst the dynamic landscape of biopharmaceutical innovation, InventisBio Co. Ltd. stands as a testament to cutting-edge drug discovery and development. Founded in 2013, this Shanghai-based company carves its niche by focusing on novel small-molecule therapeutics. The company's prowess lies in its ability to combine deep scientific expertise with robust research methodologies, positioning itself as a key player in addressing unmet medical needs, particularly in oncology and metabolic diseases. By leveraging its proprietary technology platforms, InventisBio designs and synthesizes innovative compounds, pushing them through rigorous preclinical and clinical evaluations. This strategy showcases the company’s commitment to bringing first-in-class and best-in-class drugs to the market, underscoring its drive to reshape therapeutic paradigms. InventisBio's revenue model pivots around strategic partnerships, collaborations, and licensing agreements, which enable the monetization of its scientific breakthroughs. The firm collaborates with major pharmaceutical companies, academia, and research institutions, sharing risks and benefits in advancing its pipeline. Additionally, by out-licensing its drug candidates at various development stages, InventisBio capitalizes on milestone payments and royalties. This blend not only fuels its research endeavors but also ensures a steady influx of capital to sustain its operations. Such a framework exemplifies how InventisBio has adeptly harmonized scientific ingenuity with business acumen, positioning itself as a formidable entity in the global pharmaceutical arena.
See Also
What is InventisBio Co Ltd's Revenue?
Revenue
168.8m
CNY
Based on the financial report for Dec 31, 2024, InventisBio Co Ltd's Revenue amounts to 168.8m CNY.
What is InventisBio Co Ltd's Revenue growth rate?
Revenue CAGR 5Y
25%
Over the last year, the Revenue growth was -9%.